User login
Key clinical point: Sacituzumab govitecan outperformed chemotherapy in terms of overall survival outcomes and showed a manageable safety profile in patients with pretreated, endocrine-resistant hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (BC) who had limited treatment options.
Major finding: Sacituzumab govitecan vs chemotherapy improved overall survival by 3.2 months (hazard ratio 0.79; P = .020). No new adverse events (AE) were reported; however, 1 fatal AE (septic shock caused by neutropenic colitis) was determined to be related to sacituzumab govitecan treatment.
Study details: Findings are from the phase 3 TROPiCS-02 study including 543 patients with pretreated, endocrine-resistant HR+/HER2− metastatic BC who were randomly assigned to receive either sacituzumab govitecan or single-agent chemotherapy of physician’s choice.
Disclosures: This study was funded by Gilead Sciences. Six authors declared being current or former employees of and owning stocks in Gilead Sciences, and several other authors declared ties with various sources, including Gilead Sciences.
Source: Rugo HS et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Aug 23). doi: 10.1016/S0140-6736(23)01245-X
Key clinical point: Sacituzumab govitecan outperformed chemotherapy in terms of overall survival outcomes and showed a manageable safety profile in patients with pretreated, endocrine-resistant hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (BC) who had limited treatment options.
Major finding: Sacituzumab govitecan vs chemotherapy improved overall survival by 3.2 months (hazard ratio 0.79; P = .020). No new adverse events (AE) were reported; however, 1 fatal AE (septic shock caused by neutropenic colitis) was determined to be related to sacituzumab govitecan treatment.
Study details: Findings are from the phase 3 TROPiCS-02 study including 543 patients with pretreated, endocrine-resistant HR+/HER2− metastatic BC who were randomly assigned to receive either sacituzumab govitecan or single-agent chemotherapy of physician’s choice.
Disclosures: This study was funded by Gilead Sciences. Six authors declared being current or former employees of and owning stocks in Gilead Sciences, and several other authors declared ties with various sources, including Gilead Sciences.
Source: Rugo HS et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Aug 23). doi: 10.1016/S0140-6736(23)01245-X
Key clinical point: Sacituzumab govitecan outperformed chemotherapy in terms of overall survival outcomes and showed a manageable safety profile in patients with pretreated, endocrine-resistant hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (BC) who had limited treatment options.
Major finding: Sacituzumab govitecan vs chemotherapy improved overall survival by 3.2 months (hazard ratio 0.79; P = .020). No new adverse events (AE) were reported; however, 1 fatal AE (septic shock caused by neutropenic colitis) was determined to be related to sacituzumab govitecan treatment.
Study details: Findings are from the phase 3 TROPiCS-02 study including 543 patients with pretreated, endocrine-resistant HR+/HER2− metastatic BC who were randomly assigned to receive either sacituzumab govitecan or single-agent chemotherapy of physician’s choice.
Disclosures: This study was funded by Gilead Sciences. Six authors declared being current or former employees of and owning stocks in Gilead Sciences, and several other authors declared ties with various sources, including Gilead Sciences.
Source: Rugo HS et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Aug 23). doi: 10.1016/S0140-6736(23)01245-X